Wire · opportunities
ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
Shanghai Ark Biopharmaceutical’s RSV antiviral drug ziresovir received FDA approval to enter a multicenter phase II trial focusing on severely ill infants requiring pediatric intensive care in the US, marking a crucial step towards targeted treatment for a critical unmet medical need.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now enter a high-barrier market in infant antiviral treatment as the FDA opens the door to targeted RSV therapy in critical care. Take this chance to prepare for competition in respiratory antiviral drugs or parallel clinical development.
◆ Coverage
1 source · 17 Aug 2026
◆ Related on Wire
◆ Topics